Howard Stern TRT: The Evidence Base Behind His Protocol

What Howard Stern Has Said About TRT

Howard Stern has mentioned testosterone therapy on his SiriusXM program on multiple occasions over the years. He has described it as part of a broader effort to maintain energy, mood stability, and physical condition as he has aged. These statements are self-reported on-air disclosures, not medical records, and should be treated as such.

Stern has not published a detailed protocol. Any specific clinical interpretation of what he uses must be labeled as inference from publicly available context.

What Can Be Inferred Clinically

Men in their 60s and 70s who describe fatigue, reduced libido, or mood changes consistent with hypogonadism are candidates for evaluation under the Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy. That guideline recommends confirming low testosterone on at least two fasting morning samples before initiating any treatment. [1]

Given Stern's age and the symptoms he has described publicly, a clinician would typically order total testosterone, free testosterone, LH, FSH, and a complete metabolic panel before writing a prescription. This is standard diagnostic workup, not a celebrity-specific approach.

Inference vs. Confirmed Fact

Confirmed: Stern has acknowledged TRT use on-air. Inferred: The specific formulation, dose, and monitoring schedule are not publicly known. Not supported: Any claim that his protocol deviates from or exceeds standard-of-care ranges.

The Clinical Diagnosis That Precedes Any TRT Protocol

TRT is not appropriate for all men who feel tired. Diagnosis of hypogonadism requires both symptoms and biochemical confirmation. The Endocrine Society defines low testosterone as a total serum level below 300 ng/dL on two separate morning measurements. [1]

Symptoms Required for Diagnosis

The 2018 Endocrine Society guideline lists these as the most specific symptoms of androgen deficiency in adult men: decreased libido, reduced spontaneous erections, loss of body hair, hot flushes, gynecomastia, very small testes, and infertility. [1] Less specific symptoms, including fatigue, depressed mood, and reduced physical endurance, can overlap with many other conditions and require clinical judgment.

Laboratory Workup Before Prescribing

A complete pre-treatment panel should include:

• Total testosterone (two fasting morning samples, 8:00 to 10:00 a.m.)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH (to classify primary vs. Secondary hypogonadism)
• Prolactin (if secondary hypogonadism is suspected)
• Hematocrit and hemoglobin
• PSA in men over 40
• Lipid panel and fasting glucose

The American Urological Association's 2018 guideline on testosterone deficiency echoes this workup and adds that a diagnosis should never rest on a single lab value alone. [2]

TRT Formulations: What the Evidence Supports

Several delivery systems carry FDA approval for male hypogonadism. The choice depends on patient preference, adherence, and cost. Each has a different pharmacokinetic profile that affects dosing interval and peak-to-trough testosterone variation.

Intramuscular Testosterone Cypionate and Enanthate

Testosterone cypionate (Depo-Testosterone) and testosterone enanthate are the most widely prescribed injectable forms in the United States. Standard dosing runs 100 to 200 mg intramuscularly every 1 to 2 weeks, though many clinicians now prefer 50 to 100 mg weekly to reduce the mid-cycle energy and mood swings caused by wide peak-to-trough fluctuations. [3]

FDA labeling for testosterone cypionate injection cites a half-life of approximately 8 days, which means weekly dosing produces steadier serum levels than biweekly dosing. [3]

Topical Gels and Transdermal Patches

Testosterone gel 1% (AndroGel) and 1.62% (AndroGel 1.62%) deliver testosterone transdermally and are dosed daily. The IPASS study (N=1,486) found that 77.7% of men using testosterone gel 1% achieved mid-normal range total testosterone (400 to 700 ng/dL) at 6 months. [4] Skin transfer to female partners or children is a documented safety concern that requires hand washing and covering the application site.

Subcutaneous Pellets

Testosterone pellets (Testopel) are implanted subcutaneously every 3 to 6 months. Each pellet contains 75 mg of crystalline testosterone. Typical implantation involves 6 to 12 pellets per session for a total dose of 450 to 900 mg. Serum levels peak at 1 month and decline gradually. A prospective study published in the Journal of Sexual Medicine (N=130) found pellets maintained testosterone above 400 ng/dL in 84% of patients through 4 months. [5]

Key Clinical Trials: What the Data Actually Show

The most rigorous evidence for TRT comes from the Testosterone Trials (TTrials), a set of 7 coordinated, placebo-controlled trials funded by the National Institute on Aging and published between 2016 and 2017 in the New England Journal of Medicine and affiliated journals.

TTrials: Design and Population

The TTrials enrolled 788 men aged 65 or older with a mean baseline total testosterone of 234 ng/dL. [6] Participants were randomized to testosterone gel (targeting levels of 500 to 800 ng/dL) or placebo gel for 12 months. The seven sub-studies each examined a different outcome domain: sexual function, physical function, vitality, cognitive function, bone density, anemia, and cardiovascular markers.

TTrials: Primary Outcomes

The sexual function trial showed that testosterone increased the PDDU (Patient-Reported Desire, Desire Distress, and Function) score by 2.9 points vs. 1.5 points for placebo, a statistically significant difference (P<0.001). [6]

The physical function trial found no significant improvement in the 6-minute walk test, which was its primary endpoint. However, lean body mass increased by 1.6 kg in the testosterone group vs. A 0.1 kg decrease in the placebo group (P<0.001). [7]

The vitality trial showed modest but significant improvements in fatigue as measured by the FACIT-Fatigue scale: mean improvement of 1.2 points vs. 0.4 points for placebo (P = 0.01). [8]

TRAVERSE Trial: Cardiovascular Safety

The cardiovascular safety of TRT was answered more definitively by the TRAVERSE trial (N=5,198), published in NEJM in 2023. [9] TRAVERSE enrolled men aged 45 to 80 with hypogonadism and pre-existing cardiovascular disease or elevated cardiovascular risk. Testosterone gel 1.62% was compared to placebo over a mean follow-up of 33 months. The primary composite MACE outcome (cardiovascular death, non-fatal MI, non-fatal stroke) occurred in 7.0% of the testosterone group and 7.3% of the placebo group (hazard ratio 0.96, 95% CI 0.78 to 1.17), meeting the non-inferiority threshold. [9]

The Endocrine Society's 2018 guideline had previously advised caution in men with recent MI or stroke, but TRAVERSE data have led several professional societies to revisit that restriction. [1]

Monitoring a TRT Protocol: What Guidelines Require

Starting testosterone is only part of the clinical picture. Ongoing monitoring protects patients from the known adverse effects of supraphysiologic testosterone and from conditions that TRT can unmask or worsen.

The 3-Month Check

The Endocrine Society recommends the first follow-up laboratory draw 3 months after initiating TRT. [1] This visit should include:

• Total and free testosterone (mid-cycle for injectables, 2 to 8 hours post-application for gels)
• Hematocrit
• PSA (in men over 40)
• Review of symptom response

The target range for most men on TRT is mid-normal: 400 to 700 ng/dL. Values consistently above 700 ng/dL suggest the dose should be reduced.

Hematocrit and Polycythemia

Testosterone stimulates erythropoiesis. Hematocrit above 54% is associated with increased blood viscosity and thromboembolic risk. [1] The Endocrine Society guideline states that TRT should be withheld if hematocrit exceeds 54% until it normalizes. Dose reduction, longer dosing intervals, or a switch to a lower-bioavailability formulation (such as a gel) are standard management steps. Therapeutic phlebotomy is used in refractory cases.

Prostate Safety

TRT does not appear to cause prostate cancer, but it can accelerate growth of pre-existing subclinical disease. A meta-analysis of 18 randomized trials (N=2,351) published in the Journal of Clinical Endocrinology and Metabolism found no statistically significant increase in prostate cancer incidence with TRT vs. Placebo (RR 0.97, 95% CI 0.60 to 1.56). [10] PSA should still be checked at 3 months and annually thereafter. A confirmed rise of more than 1.4 ng/mL above baseline within any 12-month period warrants urological referral. [1]

Fertility Considerations

Exogenous testosterone suppresses the HPG axis, reducing LH and FSH and impairing spermatogenesis. Men who wish to preserve fertility should not use standard TRT. Alternatives include clomiphene citrate (off-label), human chorionic gonadotropin (hCG), or enclomiphene. A 2019 review in Fertility and Sterility found that clomiphene citrate 25 to 50 mg every other day raised total testosterone by a mean of 191 ng/dL while preserving spermatogenesis in men with secondary hypogonadism. [11]

Body Composition and Aging: Why Men in Their 60s Consider TRT

Age-related decline in testosterone (sometimes called late-onset hypogonadism or age-related hypogonadism) is distinct from classical hypogonadism caused by pituitary or gonadal pathology. Total testosterone falls roughly 1 to 2% per year after age 30 in healthy men, and free testosterone declines faster due to rising sex hormone-binding globulin (SHBG). [12]

Lean Mass and Strength

The TTrials lean mass finding (+1.6 kg at 12 months) is consistent with earlier data from a 2010 NEJM meta-analysis by Bhasin et al. (N=1,084 across 29 trials), which found testosterone supplementation increased lean mass by a mean of 1.73 kg and reduced fat mass by 1.63 kg compared to placebo. [13] Muscle strength improved modestly but consistently in grip strength testing.

Bone Density

The TTrials bone sub-study (N=211) found that testosterone gel increased volumetric bone mineral density at the spine by 7.5% and trabecular bone score by 11.4% at 12 months, both significantly greater than placebo. [14] For older men with osteopenia, this may be a secondary benefit of TRT beyond symptom relief.

Cognitive Function

The TTrials cognitive sub-study found no significant benefit of testosterone on cognitive function as measured by the Cognitive Function Instrument or a composite battery at 12 months. [15] The Endocrine Society guideline does not list cognitive improvement as an established indication for TRT. This is an area where public perception of TRT's benefits may outpace the current evidence.

How a Standard TRT Protocol Is Structured

A typical TRT initiation protocol, based on the Endocrine Society 2018 guideline and AUA 2018 testosterone deficiency guideline, follows this sequence:

1. Confirm hypogonadism with two morning total testosterone levels below 300 ng/dL plus at least one symptom.
2. Rule out secondary causes: pituitary MRI if LH/FSH is low and prolactin is elevated.
3. Choose a formulation based on patient preference, cost, and adherence.
4. Start at a conservative dose: for testosterone cypionate, 100 mg IM weekly or 200 mg IM every 2 weeks.
5. Check testosterone, hematocrit, and PSA at 3 months.
6. Adjust dose to target mid-normal range (400 to 700 ng/dL).
7. Recheck every 6 months once stable.

This framework applies to any patient, including men in Stern's demographic of 60s to 70s with self-reported fatigue and mood changes.

Risks and Contraindications

TRT is contraindicated in men with active or suspected prostate or breast cancer, untreated severe obstructive sleep apnea, hematocrit above 50% at baseline, severe untreated lower urinary tract symptoms, or a recent (within 6 months) cardiovascular event. [1]

Sleep apnea deserves special attention. Testosterone can worsen obstructive sleep apnea by increasing upper airway collapsibility. A 2014 study in JAMA Internal Medicine (N=67) found that testosterone therapy worsened apnea severity (AHI increase of 8.4 events/hour) in older men with mobility limitations compared to placebo. [16] Screening with the STOP-BANG questionnaire before initiating TRT is a reasonable standard-of-care step.

What the Endocrine Society and AUA Say

Two key professional society documents guide TRT prescribing in the United States.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We recommend testosterone therapy for men with classic androgen deficiency syndromes who have symptoms and signs consistent with androgen deficiency and consistently low serum testosterone concentrations." [1]

The AUA's 2018 Guideline on Evaluation and Management of Testosterone Deficiency adds: "Testosterone therapy is not recommended for patients who are actively trying to father a child, have a baseline hematocrit greater than 50%, have untreated severe obstructive sleep apnea, or have experienced a major adverse cardiovascular event in the past 6 months." [2]

Both documents emphasize that the goal of TRT is symptom resolution in the context of confirmed biochemical deficiency, not optimization of testosterone to supraphysiologic levels.